#USA #New York #Faruqi & Faruqi #Investors Alert #Capricor Therapeutics

Urgent Notice for Capricor Investors

Faruqi & Faruqi, LLP, a prominent national securities law firm, is bringing attention to investors of Capricor Therapeutics, Inc. (NASDAQ: CAPR) about a significant upcoming deadline. Investors who have incurred losses in Capricor's shares should pay close attention to the approaching September 28, 2026 deadline to seek the role of lead plaintiff in a federal securities class action against the company.

Key Information

The class action lawsuit involves accusations against Capricor and its executives for violating federal securities laws. The allegations state that the company made misleading statements throughout a specified period, which significantly resulted in financial losses for investors. This timeframe spans from December 17, 2025, to July 26, 2026, coinciding with the period during which many individuals purchased or acquired Capricor securities. Investors in this period are being urged to consider their legal rights and may wish to discuss their options with legal counsel.

What Investors Should Do

Josh Wilson, a Senior Partner at Faruqi & Faruqi, is encouraging all affected investors to reach out to him directly for personalized legal guidance. Interested parties are advised to act promptly, as the deadline for the motion to serve as lead plaintiff is swiftly approaching. For those who wish to lead the effort in this class action, it's crucial to take immediate action.

If you are looking to participate, you can obtain more information through the firm's direct lines at 877-247-4292 or 212-983-9330 (Ext. 1310). Investors can decide to either engage in the legal process as a lead plaintiff or choose to remain an absent member of the class, without affecting their ability to share in any recovery that may arise from the lawsuit.

Allegations Overview

The allegations surrounding the lawsuit focus on a few key points:
1. Changes to the planned statistical analysis regarding Deramiocel were not agreed to beforehand by the FDA.
2. The company resubmitted its Biologics License Application (BLA) with these unreceived changes, potentially jeopardizing its approval status.
3. There is a considerable risk that the FDA may find that the clinical outcomes of Deramiocel fail to show substantial efficacy.
4. Consequently, after these misleading communications, Capricor's stock plummeted nearly 64% after the disclosures of these facts came to light on July 27, 2026.

The Importance of Legal Representation

It’s essential for investors affected by Capricor’s circumstances to have effective legal representation capable of navigating the complexities of securities litigation. Faruqi & Faruqi prides itself on its expertise in this field, assisting numerous investors in similar situations and recovering substantial sums for their clients. This firm has several offices dispersed across New York, Pennsylvania, California, and Georgia, ensuring convenience and access for all involved.

In summary, if you were an investor in Capricor Therapeutics during the class period indicated, now is the time to seek the counsel you need. Your rights as an investor could be compromised if you do not act within the defined legal timeframe. Be proactive, protect your investments, and consult with professionals!

For continuous updates and more insights from Faruqi & Faruqi, follow them on LinkedIn, X, or Facebook. We emphasize that this communication serves as an advertisement and that prior results do not assure similar outcomes for future cases.